OncoMatch/Clinical Trials/NCT06586658
Anti-CD70-CAR-T Cell Injection for the Treatment of Locally Advanced or Relapsed/Metastatic CD70+ Inoperable Renal Cells
Is NCT06586658 recruiting? Yes, currently enrolling (Jun 2026). This Early Phase 1 trial studies anti-CD70-CAR-T cells for renal cell carcinoma.
Treatment: anti-CD70-CAR-T cells — This is an investigator-initiated trial to evaluate the role of anti-CD70-CAR T cells in locally advanced or recurrent/metastatic renal cell carcinoma that is inoperable.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Renal Cell Carcinoma
Biomarker criteria
Required: CD70 overexpression (CD70+)
advanced malignant renal cell carcinoma of CD70+
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: vegfr inhibitor
Must have received: checkpoint inhibitor
Cannot have received: car-t cell therapy
Cannot have received: anti-cd70 therapy
Lab requirements
Blood counts
Neutrophil absolute value ≥1.5×10^9/L; Hemoglobin ≥80g/L; Platelets ≥75×10^9/L; Lymphocytes (ALC) ≥0.3×10^9/L; no blood transfusion or cell growth factor therapy within 7 days prior to evaluation (2 weeks for long-acting agents such as PEG-rhG-CSF, recombinant erythropoietin allowed)
Kidney function
creatinine ≤1.5×ULN or endogenous creatinine clearance ≥50 mL/min (using Cockcroft Gault formula)
Liver function
serum total bilirubin ≤1.5× ULN (for Gilbert syndrome patients, total bilirubin ≤3×ULN), AST, ALT ≤2.5×ULN; If there is liver metastasis, allow AST, ALT≤5×ULN
Cardiac function
Left ventricular ejection fraction (LVEF) of echocardiography was ≥50%
Have sufficient hematologic function ... Adequate liver function ... Adequate renal function ... Left ventricular ejection fraction (LVEF) of echocardiography was ≥50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06586658 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior car-t cell therapy, anti-cd70 therapy disqualifies patients from enrollment.
Does this trial require CD70?
Yes, CD70 overexpression is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 70 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages